Search for a trial

A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally once during an acute migraine attack of moderate or severe intensity

Supported by the observation from the Phase I studies in healthy volunteers, doses within a range of 50 to 500 mg are safe and well tolerated. This Phase II trial will be performed to:a. obtain proof of concept of BI 44370 TAb. perform dose finding…

Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a
randomized placebo-controlled study

This study has been transitioned to CTIS with ID 2024-520305-39-00 check the CTIS register for the current data. Primary objective: to evaluate the efficacy of LSD 25µg every 3 days for 3 weeks in cCH. Additional objectives:- To evaluate the safety…